Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04360200

Cognitive Impairment in Ageing People

Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of cognitive disorders.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China

Location status: Recruiting

Location contact

Yamei Tang, M. D., Ph. D

PRINCIPAL_INVESTIGATOR

Yamet Tang, M. D., Ph. D

CONTACT

[email protected]

86-020-34070569

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 50 years old.
  • Sign informed consent.
  • According to DSM-IV, the diagnostic standard of dementia was not met.
  • The clinical dementia rating (CDR) was 0.5.

Exclusion criteria

  • Subjects with mental retardation.
  • Refuse to have blood sampling, imaging and other examinations.
  • Uncooperative subjects that have serious organic diseases, or have a history of mental illness, or have physical disability (including severe aphasia).
  • Contraindications of MR scanning.
  • Suffering from serious physical or mental illness.

Treatment and study plan

Primary outcomes

  1. Incidence of Dementia

    Time frame: April 2020 to December 2040

Secondary outcomes

  1. The conversion rate of normal elderly to MCI to neurocognitive disorder

    Time frame: April 2020 to December 2040

  2. Improvement of Cognitive Function based on Montreal Cognitive Assessment (MoCA) score

    Time frame: April 2020 to December 2040

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Yamei Tang

Other

Registry information

Official study title

Cognitive Impairment in Ageing People: A Longitudinal Observational Prospective Study

Important dates

Study start
2020
Primary completion
2040
Study completion
2040
First posted
Apr 24, 2020
Registry last updated
Sep 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.